To the Editor We read with interest the article by Alegría-Landa et al1 in a recent issue of JAMA Dermatology reporting on 33 patients with histiocytoid Sweet syndrome (HSS). Their novel immunohistochemical findings clearly show that the dermal infiltrate in HSS is mostly composed of myeloid nuclear differentiation antigen–positive and myeloperoxidase–positive (MPO+) immature myeloid cells, and not of histiocytes or M2 macrophages. We support that the skin-infiltrating myeloid nonblastic cells in HSS should not be interpreted as leukemia cutis, ie, as an infiltrate of blastic myeloid cells.
Vignon-Pennamen MD, Osio A, Battistella M. Histiocytoid Sweet Syndrome and Myelodysplastic Syndrome. JAMA Dermatol. 2017;153(8):835–836. doi:10.1001/jamadermatol.2017.1669
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: